| Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration A Meliani, F Boisgerault, R Hardet, S Marmier, F Collaud, G Ronzitti, ... Nature communications 9 (1), 4098, 2018 | 213 | 2018 |
| Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase F Puzzo, P Colella, MG Biferi, D Bali, NK Paulk, P Vidal, F Collaud, ... Science translational medicine 9 (418), eaam6375, 2017 | 119 | 2017 |
| Exposure to wild-type AAV drives distinct capsid immunity profiles in humans K Kuranda, P Jean-Alphonse, C Leborgne, R Hardet, F Collaud, ... The Journal of clinical investigation 128 (12), 5267-5279, 2018 | 92 | 2018 |
| Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A BR Long, P Veron, K Kuranda, R Hardet, N Mitchell, GM Hayes, WY Wong, ... Molecular Therapy 29 (2), 597-610, 2021 | 51 | 2021 |
| Role of regulatory T cell and effector T cell exhaustion in liver-mediated transgene tolerance in muscle J Poupiot, HC Verdera, R Hardet, P Colella, F Collaud, L Bartolo, ... Molecular Therapy-Methods & Clinical Development 15, 83-100, 2019 | 22 | 2019 |
| Gene therapy: paving new roads in the treatment of hemophilia GG Yamaguti-Hayakawa, MC Ozelo Seminars in thrombosis and hemostasis 45 (07), 743-750, 2019 | 20 | 2019 |
| Intrinsic Transgene Immunogenicity Gears CD8+ T-cell Priming After rAAV-Mediated Muscle Gene Transfer M Carpentier, S Lorain, P Chappert, M Lalfer, R Hardet, D Urbain, ... Molecular Therapy 23 (4), 697-706, 2015 | 19 | 2015 |
| Oral-tolerization prevents immune responses and improves transgene persistence following gene transfer mediated by adeno-associated viral vector R Hardet, B Chevalier, L Dupaty, Y Naïmi, G Riou, L Drouot, L Jean, ... Molecular Therapy 24 (1), 87-95, 2016 | 17 | 2016 |
| Evaluation of P2X7 receptor function in tumor contexts using raav vector and nanobodies (AAVnano) M Demeules, A Scarpitta, C Abad, H Gondé, R Hardet, C Pinto-Espinoza, ... Frontiers in oncology 10, 1699, 2020 | 16 | 2020 |
| A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7 In Vivo H Gondé, M Demeules, R Hardet, A Scarpitta, M Junge, C Pinto-Espinoza, ... Frontiers in Immunology 12, 704408, 2021 | 9 | 2021 |
| Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo M Demeules, A Scarpitta, R Hardet, H Gondé, C Abad, M Blandin, ... Frontiers in Immunology 13, 1012534, 2022 | 4 | 2022 |
| Development of antibody and nanobody tools for P2x7 T Stähler, W Danquah, M Demeules, H Gondé, R Hardet, F Haag, ... The P2X7 Receptor: Methods and Protocols, 99-127, 2022 | 3 | 2022 |
| Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy AC Franke, R Hardet, L Prager, M Bentler, M Demeules, P John-Neek, ... Molecular Therapy-Methods & Clinical Development 29, 238-253, 2023 | 2 | 2023 |
| Whole-body rescue of Pompe disease with AAV liver delivery of engineered secretable GAA transgenes P Colella, F Puzzo, M Biferi, D Bali, N Paulk, P Vidal, F Collaud, ... Neuromuscular Disorders 27, S246, 2017 | 2 | 2017 |
| Oral Tolerance: Another Reason to Eat Your Veggies! R Hardet, F Mingozzi Molecular Therapy 25 (2), 311-313, 2017 | 2 | 2017 |
| Modifying immune responses to adeno-associated virus vectors by capsid engineering M Bentler, R Hardet, M Ertelt, D Rudolf, D Kaniowska, A Schneider, ... Molecular Therapy-Methods & Clinical Development 30, 576-592, 2023 | 1 | 2023 |
| Continued characterization of the immune response in a phase-1/2 clinical study of valoctocogene roxaparvovec, an AAV5 mediated gene therapy for hemophilia A B Long, B Kim, WY Wong, K Yang, C Vettermann, K Yu, K Lau, R Hardet, ... Haemophilia 25, 59-59, 2019 | 1 | 2019 |
| Immune checkpoint regulation of cardiac lymphatic remodeling in cardiovascular diseases T Lemarcis, C Héron, C Valentin, C Thuiliiez, M Valet, G Riou, R Hardet, ... Archives of Cardiovascular Diseases Supplements 15 (1), 116, 2023 | | 2023 |
| AAV-mediated induction of immunogenic cell death to promote anti-tumor immune responses A Scarpitta, R Hardet, M Bentler, M Demeules, M Blandin, U Hacker, ... HUMAN GENE THERAPY 33 (23-24), A7-A7, 2022 | | 2022 |
| Towards a single-shot prime-boost AAV-based vaccine for cancer immunotherapy A Franke, R Hardet, L Prager, M Bentler, M Demeules, N Jaeschke, ... HUMAN GENE THERAPY 32 (19-20), A34-A34, 2021 | | 2021 |
Giuseppe RonzittiINSERM Tenured researcher, Principal Investigator, GenethonVerified email at genethon.fr
